Bacterial Respiratory Infections Therapeutics
1. Factive patent expiration
Treatment: Method of treating bacterial infections; Use of quinolone compounds against anaerobic pathogenic bacteria; Use of quinolone compounds against pneumococcal pathogenic bacteria; Use of quinolone compoun...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5962468 | LG CHEM LTD | 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1- cyclopropyl-6-fluoro-4-oxo-1, 4-dihydro-1, 8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Jun, 2015
(10 years ago) | |
| US6455540 | LG CHEM LTD | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
Sep, 2019
(6 years ago) | |
| US5633262 | LG CHEM LTD | Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituent and processes for preparing thereof |
Jun, 2015
(10 years ago) | |
| US6803376 | LG CHEM LTD | Method of use of quinolone compounds against pneumococcal and haemophilus bacteria |
Sep, 2019
(6 years ago) | |
| US6340689 | LG CHEM LTD | Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria |
Sep, 2019
(6 years ago) | |
| US5776944 | LG CHEM LTD | 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof |
Apr, 2017
(8 years ago) | |
| US6723734 | LG CHEM LTD | Salt of naphthyridine carboxylic acid derivative |
Mar, 2018
(7 years ago) | |
| US6331550 | LG CHEM LTD | Methods of use of quinolone compounds against anaerobic pathogenic bacteria |
Sep, 2019
(6 years ago) | |
| US6262071 | LG CHEM LTD | Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria |
Sep, 2019
(6 years ago) | |
Drugs and Companies using GEMIFLOXACIN MESYLATE ingredient
Market Authorisation Date: 04 April, 2003
Dosage: TABLET
How can I launch a generic of FACTIVE before it's drug patent expiration?
More Information on Dosage
FACTIVE family patents
